BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1521 related articles for article (PubMed ID: 12546563)

  • 1. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
    San Juan AA
    Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
    Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
    Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
    Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
    Zhang H; Li H; Ma Q
    J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
    Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
    Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.
    Shah P; Siddiqi MI
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
    He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
    J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Ashek A; Cho SJ
    Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
    Hu X; Stebbins CE
    Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.